Shopping Cart

Your shopping cart is currently empty

Umeclidinium bromide

Name: Umeclidinium bromide
Brand: TargetMol
SKU: T4997
Price: 34 USD
Availability: InStock
Rating: 5 (10 reviews)

🥰Excellent

Catalog No. T4997Cas No. 869113-09-7

Alias GSK573719A

Umeclidinium bromide (GSK573719A) is a novel mAChR antagonist.

Umeclidinium bromide

🥰Excellent

Purity: 99.89%

Catalog No. T4997Alias GSK573719ACas No. 869113-09-7

Umeclidinium bromide (GSK573719A) is a novel mAChR antagonist.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$34	In Stock	In Stock
2 mg	$48	In Stock	In Stock
5 mg	$77	In Stock	In Stock
10 mg	$126	In Stock	In Stock
25 mg	$223	In Stock	In Stock
50 mg	$369	In Stock	In Stock
100 mg	$553	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$89	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.89%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Bioactivity

Description	Umeclidinium bromide (GSK573719A) is a novel mAChR antagonist.
Targets&IC50	M2 mAChR:0.15 nM（Ki）, M4 mAChR:0.05 nM（Ki）, M3 mAChR:0.06 nM（Ki）, M1 mAChR:0.16 nM（Ki）, M5 mAChR:0.13 nM（Ki）
In vitro	In human embryonic kidney 293 cells, Umeclidinium bromide (GSK573719A) inhibits the human ether-a-go-go-related gene channel tail current in a concentration-dependent manner (IC50 = 9.4 μM).
In vivo	Administering Umeclidinium bromide (GSK573719A) intranasally at a dose of 0.025 μg to mice once daily for five days incrementally enhances its inhibitory effect on bronchomotor tone, with inhibition increasing from 35% after the first dose to 60% by the fifth day. Following a five-day rest period, where bronchomotor tone reverts to baseline, a subsequent dose yields an inhibition level comparable to that of the initial dose, indicating the absence of tolerance development with repeated intranasal administration. Conversely, oral administration of Umeclidinium bromide at 2.0 mg/kg, equivalent to 100 times the intranasal ED50 value, fails to offer any protective effect against an Mch challenge, demonstrating the method-specific efficacy of this compound.
Animal Research	Mice:Age-matched male BALB/c mice (23-25 gm) are pretreated intranasally (50 μL per mouse) with vehicle (0.9% saline) or Umeclidinium bromide at intervals (0.25-48 hours) prior to methacholine challenge, and placed into individual plethysmograph chambers. Fresh air is supplied by bias flow pumps to the chambers. After baseline respiratory [enhanced pause (Penh)] values are collected, the mice received methacholine (30 mg/mL or EC80) by aerosol delivery (flow=1.6 mL/min×2 minutes). An average Penh is then calculated for 5 minutes. Penh=[(expiratory time/relaxation time)?1]×(peak expiratory flow/peak inspiratory flow), and relaxation time is the amount of time required for 70% of the tidal volume to expire. In some cases, animals are treated on multiple, consecutive days as described in the figure legends. The data are expressed as the mean±S.E.M. percent inhibition of Penh or (mean Penh value of vehicle treated group-Penh for each drug-treated animal) divided by (mean Penh value of vehicle treated group)×100%. Data are analyzed using commercially available software.
Synonyms	GSK573719A

Chemical Properties

Molecular Weight	508.49
Formula	C₂₉H₃₄BrNO₂
Cas No.	869113-09-7
Smiles	[Br-].OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2
Relative Density.	no data available

Storage & Solubility Information

Storage

keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 34 mg/mL (66.86 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Saline: 2 mg/mL (3.93 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.9666 mL	9.8330 mL	19.6661 mL	98.3304 mL
5 mM	0.3933 mL	1.9666 mL	3.9332 mL	19.6661 mL
10 mM	0.1967 mL	0.9833 mL	1.9666 mL	9.8330 mL
20 mM	0.0983 mL	0.4917 mL	0.9833 mL	4.9165 mL
50 mM	0.0393 mL	0.1967 mL	0.3933 mL	1.9666 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc